Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Cancer targets in the Ras pathway.

Rodriguez-Viciana P, Tetsu O, Oda K, Okada J, Rauen K, McCormick F.

Cold Spring Harb Symp Quant Biol. 2005;70:461-7. Review.

PMID:
16869784
2.

Raf: a strategic target for therapeutic development against cancer.

Beeram M, Patnaik A, Rowinsky EK.

J Clin Oncol. 2005 Sep 20;23(27):6771-90. Review.

PMID:
16170185
3.

Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.

Gollob JA, Wilhelm S, Carter C, Kelley SL.

Semin Oncol. 2006 Aug;33(4):392-406. Review.

PMID:
16890795
4.

Tailoring Ras-pathway--inhibitor combinations for cancer therapy.

Blum R, Kloog Y.

Drug Resist Updat. 2005 Dec;8(6):369-80. Epub 2005 Dec 13. Review.

PMID:
16356760
5.

Oncogene products as therapeutic targets for cancer.

Huang PS, Heimbrook DC.

Curr Opin Oncol. 1997 Jan;9(1):94-100. Review.

PMID:
9090500
6.

Ras signaling and therapies.

Young A, Lyons J, Miller AL, Phan VT, Alarcón IR, McCormick F.

Adv Cancer Res. 2009;102:1-17. doi: 10.1016/S0065-230X(09)02001-6. Review.

PMID:
19595305
7.

Biomarkers downstream of RAS: a search for robust transcriptional targets.

Györffy B, Schäfer R.

Curr Cancer Drug Targets. 2010 Dec;10(8):858-68. Review.

PMID:
20718707
8.

Inhibitors of the ras oncogene as therapeutic targets.

Ghobrial IM, Adjei AA.

Hematol Oncol Clin North Am. 2002 Oct;16(5):1065-88. Review.

PMID:
12512383
9.

Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery.

Thompson N, Lyons J.

Curr Opin Pharmacol. 2005 Aug;5(4):350-6. Review.

PMID:
15955734
10.

[Targeting the RAS signalling pathway in cancer].

Mansi L, Viel E, Curtit E, Medioni J, Le Tourneau C.

Bull Cancer. 2011 Oct;98(9):1019-28. doi: 10.1684/bdc.2011.1380. Review. French.

PMID:
21715253
11.

[Progress in the study of antitumor drug targeting on the Ras signaling pathway].

Zhu YJ, Jiang FC.

Yao Xue Xue Bao. 2009 Jan;44(1):1-10. Review. Chinese.

PMID:
19350814
12.

Blocking oncogenic Ras signaling for cancer therapy.

Adjei AA.

J Natl Cancer Inst. 2001 Jul 18;93(14):1062-74. Review.

13.

Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007--present).

Sacco E, Spinelli M, Vanoni M.

Expert Opin Ther Pat. 2012 Nov;22(11):1263-87. doi: 10.1517/13543776.2012.728586. Epub 2012 Sep 26. Review.

PMID:
23009088
14.

RAS: target for cancer therapy.

Saxena N, Lahiri SS, Hambarde S, Tripathi RP.

Cancer Invest. 2008 Nov;26(9):948-55. doi: 10.1080/07357900802087275. Review.

PMID:
18798058
15.

In search of novel molecular targets in cancer: the diacyglycerol pathways.

Lorenzo PS.

Hawaii Med J. 2004 Oct;63(10):318-9, 321. Review. No abstract available.

PMID:
15570721
16.

The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.

Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF.

Curr Cancer Drug Targets. 2008 May;8(3):187-98. Review.

PMID:
18473732
17.

New druggable targets in the Ras pathway?

Matallanas D, Crespo P.

Curr Opin Mol Ther. 2010 Dec;12(6):674-83. Review.

PMID:
21154159
18.

Targeting RAS signalling pathways in cancer therapy.

Downward J.

Nat Rev Cancer. 2003 Jan;3(1):11-22. Review.

PMID:
12509763
19.

Recent advances in the research and development of RAF kinase inhibitors.

Smith RA, Dumas J, Adnane L, Wilhelm SM.

Curr Top Med Chem. 2006;6(11):1071-89. Review.

PMID:
16842147
20.

Is B-Raf a good therapeutic target for melanoma and other malignancies?

Madhunapantula SV, Robertson GP.

Cancer Res. 2008 Jan 1;68(1):5-8. doi: 10.1158/0008-5472.CAN-07-2038. Review.

Items per page

Supplemental Content

Write to the Help Desk